The results observed in the previously mentioned Dunbar study are similar to results achieved by other potent fluoroquinolones, such as moxifloxacin and gemifloxacin. While no randomized clinical trial has yet been performed to compare the 750 mg dose of levofloxacin to another fluoroquinolone, there has been a recent trial comparing the 500 mg once-daily dose of levofloxacin with a 400 mg once daily dose of moxifloxacin in patients with CAP requiring hospitalization and who were older than 65 years of age and with comorbidities (these are patients at risk of serious disease) (9). This was a prospective, double-blind trial and cure rates were similar for the clinically evaluable population. Another report from this same trial specifically addressed the cardiac safety of moxifloxacin and levofloxacin in these patients (10). The primary endpoint was a composite of ventricular arrhythmia events which occurred during Holter monitoring. These events were documented in 8.3% of moxifloxacin-treated patients and 5.1% of levofloxacin-treated patients (p = 0.29).